The basics:

• Lura Health announces partnership with Japan-based SCO Global
• Deal aims to deploy salivary sensors in Asian clinical settings
• Pilot projects with Japanese universities begin this fall
• Lura Health targets FDA approval by early 2027

Lura Health marked its latest milestone, announcing Aug. 5 it entered into an investment and business partnership with Japan-based SCO Global.

NJBIZ has reported previously on Lura Health. The health tech company led by co-founder and CEO Daniel Weinstein has created the world’s first continuous intraoral salivary monitoring sensor. Lura Health is also an original participant at HAX in Newark, the hard tech accelerator program that NJBIZ featured in its July 28 issue.

The Newark-based company says it is pioneering a new health care model. Lura Health aims to visualize whole-body health from within the oral cavity. The SCO Global partnership aims to deploy Lura Health’s intraoral senor technology into clinical use in Asia and expand its applications globally.

Key things to know:

• Lura Health is developing wearable microsensors to wear inside the mouth. The tech either attaches to dental appliances or bonds directly to a tooth. The device collects real-time biometric data, such as pH levels and metabolites in saliva
• SCO Group operates Pay Light X, an integrated dental clinic management platform in Japan
• Lura Health aims to establish a new model for preventative care in Japan. It will integrate its sensor technology with SCO Group’s clinical infrastructure to deliver the technology seamlessly to clinicians and patients
• Joint pilot project with Japanese universities and research institutions expect to begin this fall
• Lura Health is targeting U.S. Food and Drug Administration approval by early 2027. Following that, it plans to expand its reach into Asian markets, beginning in Japan

‘The future of preventative health care‘

“We at Lura Health are honored to announce our investment and business partnership with SCO Group, a leader in digital transformation within the Japanese dental industry,” said Weinstein in an Aug. 5 press release. “This collaboration represents a major step forward in our mission to enable preventative and user-friendly health monitoring through the diagnostic power of saliva.”

“We are very pleased to partner with Lura Health, whose groundbreaking intraoral biosensing technology embodies the future of preventative health care,” said SCO Group Chairman and CEO Yusuke Tamai. “At SCO Group, we have long championed the integration of health technology into daily life, and this partnership allows us to take that mission to the next level.”

Tamai said the oral cavity is the gateway to the body’s health – yet remains one of the least-monitored areas.

Our vision aligns deeply with SCO Group’s commitment to improving the well-being of individuals through technology.
— Daniel Weinstein, co-founder and CEO, Lura Health

“By utilizing saliva – a highly accessible source of biological data – we aim to convert invisible health risks into visible insights,” said Tamai.

“Our vision aligns deeply with SCO Group’s commitment to improving the well-being of individuals through technology,” said Weinstein. “Together, we will combine our sensor innovations with their extensive health care network to create tangible societal impact.

“We look forward to deploying our sensors in real-world clinical settings and co-developed patient-centered products based on live feedback from users in Japan.”

Lura Health says that future use cases for its technology include sports performance monitoring, elder care as well as wellness. According to the company, the focus positions its sensors as a core tool in comprehensive health management.